Juneau Biosciences Presents New Genetic Discoveries In Endometriosis At Asrm Scientific Congress & Expo

Presentation at premier infertility conference by Predictive Technology Group subsidiary awarded “Best in Clinical/Population Science Prize Paper”

SALT LAKE CITY (October 9, 2018) – Predictive Technology Group, Inc. (OTC/PINK: PRED) (“Predictive”), reports that Kenneth Ward, M.D., CEO of Juneau Biosciences, LLC, presented new scientific discoveries concerning the genetics of endometriosis at the 74th American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo underway in Denver, Colo.  Juneau Biosciences is a majority-owned subsidiary of Predictive.

Dr. Ward’s paper, entitled “Can Genetic Markers of Endometriosis Predict a Patient’s Responsiveness to Leuprolide Acetate,” addresses the impact genes underlying endometriosis have on the degree of relief a patient receives when prescribed leuprolide acetate, the most widely used FDA-approved therapy for endometriosis.  Dr. Ward’s paper was recognized with the ASRM Scientific Program Committee’s “Best in Clinical/Population Science Prize Paper” research award.

On October 10 representatives from Juneau will make three additional scientific presentations based on data from Predictive’s Genealogy Database (GenDB™), exploring the use of extended family trees in disease gene discovery.  Two of these presentations examine the lineage of families with the largest presence of genes linked to endometriosis reported to date.  One family tree spans 19 generations and includes over 250 women living with surgically-confirmed endometriosis, all descendants of a man born in 1608.  Data from GenDB suggests that more than 1 million women in the United States may carry this family’s risk factor.

“Predictive is using its powerful GenDB™ database to increase the efficiency and thoroughness of gene discoveries in complex diseases,” said Bradley Robinson, CEO of Predictive Technology Group. “As Predictive scales its genomics and artificial intelligence capabilities, our objective is to transform the diagnosis, prediction and treatment of common diseases that lead to tremendous human suffering.”

Predictive and Juneau have employed state-of-the-art genomic methods to uncover hundreds of genes that play a role in endometriosis development and progression.  The companies’ population genetics research underlies the novel ARTGuide™ test, a first-of-its-kind non-invasive diagnostic test for endometriosis and other genetic causes of infertility, recently launched by Predictive subsidiary Predictive Diagnostics.

ASRM is an international and multi-disciplinary organization devoted to advancing knowledge and expertise in reproductive medicine and biology, with a particular focus on human infertility.

About Endometriosis:

Approximately 27 million women in the United States are symptomatic of endometriosis. Endometriosis occurs when the tissue similar to the lining of the uterus (womb) is found in other parts of the body, most commonly in the pelvis. Monthly bleeding and inflammation caused by these lesions may severely impact a woman’s quality of life. Some affected women experience severe pain, others infertility, others problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires surgery. Due to the difficulties, invasiveness, and expense of diagnosing the condition, the majority of women diagnosed with endometriosis suffer for over a decade before receiving treatment. Treatment may involve hormonal suppression or a targeted destruction of the abnormal tissue during surgery.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics, Predictive Diagnostics, and Predictive Biotech.  These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products.  The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively.  Additional information is available at and

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.